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 ABSTRACT 
  Temozolomide (TMZ) is an adjuvant chemotherapeutic agent used in the treatment of 
glioblastoma, in the central nervous system. However, as with all chemotherapeutic drugs, 
systemic toxicity and side-effects occur. To overcome these limitations and to improve 
temozolomide efficacy, drug delivery systems were designed based on poly (lactic-co-
glycolic acid) (PLGA) nanoparticles and liposomes. The former were produced via the single-
emulsion solvent evaporation technique and to produce the latter, the lipid film hydration 
method was utilized. The nanoparticles were characterized by size through dynamic light 
scattering and zeta potential (ζ-potential) measurements through laser Doppler velocimetry. 
The size of PLGA nanoparticles alone was 177 nm, and the ζ-potential was -31 mV; whereas 
the size of TMZ-loaded PLGA nanoparticles was 176 nm, and the ζ-potential was -2 mV. 
Liposomes alone showed a size and ζ-potential of 196 nm and -2 mV respectively; whereas 
TMZ-loaded liposomes showed a size of 195 nm and ζ-potential of -2mV. The stability and 
the encapsulation efficiency of the systems were evaluated. Although TMZ was found to be 
adsorbed onto the surface of PLGA nanoparticles instead of being encapsulated within the 
PLGA nanoparticles, promising results were obtained with liposomes and an encapsulation 
efficiency of 40-55% was achieved. Liposomes were demonstrated to be a potential 
nanocarrier for TMZ.   
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1. INTRODUCTION 
1.1 Motivation  
  Glioblastoma (GBM) is a highly malignant astrocytoma with an average overall survival 
rate of 12 months. Current therapy includes radiation and chemotherapy with the adjuvant 
chemotherapeutic agent temozolomide (TMZ), the latter increasing the overall survival to 
around 15 months. TMZ as other chemotherapeutic drugs affect both healthy as well as 
cancerous cells, leading to systemic side-effects and lower bioavailability of the drug in the 
desired site of action. Lower bioavailability leads to higher doses having to be administered 
at higher rates, increasing toxicity and often leading to chemotherapy being interrupted. 
Designing a way to overcome these drawbacks and increase treatment efficacy is therefore 
of paramount importance. Nanoparticles are being extensively studied as drug delivery 
systems (DDS) to overcome the limitations of traditional cancer therapies. 
  Physical or chemical incorporation of the drug into a particulate colloidal system such as 
liposomes, micro-nanospheres, erythrocytes, polymeric and reverse micelles, are the 
approaches foreseeable for targeted drug delivery. The design of biocompatible and 
biodegradable nanocarriers has been developed as an attractive option for DDS. Liposomes 
and poly(lactic-co-glycolic acid)  (PLGA) are both appealing choices for this particular DDS. 
Liposomes are already available on the market anti-cancer formulations such as liposomal 
doxorubicin and PLGA is the biodegradable polymer that has been investigated in different 
formulations. The polymer is approved by the FDA and for several drug delivery systems in 
humans and is available in different molecular weights and copolymer compositions.  
Both Liposomes and PLGA have very different physicochemical, biochemical and 
mechanical properties each presenting their own advantages where drug delivery is 
concerned. Functionalization, the addition of ligands specific to the target area increase 
specificity of the nanoparticle to the affected area. Several molecules selective to brain 
parenchyma and blood-brain barrier (BBB) have been studied for PLGA and liposomal 
nanocarriers although no studies have been able to functionalize TMZ-loaded PLGA or 
liposomes. Therefore, the development of a suitable DDS nanoparticle for TMZ is of high 
clinical importance. 
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1.2 Aim 
 The main objective of this dissertation project was to produce a suitable nanoparticle 
(NP) drug delivery system (DDS) for temozolomide (TMZ). In order to do this, first, the 
physicochemical properties of TMZ had to be assessed: stability at different temperatures, pH 
and behaviour in different solvents. The next step was to produce nanocarriers by using poly 
(lactic-co-glycolic acid) (PLGA) NPs, and phospholipids (liposomes). After synthesis optimization, 
TMZ-loaded NPs were produced and characterized by measuring their size, zeta-potential and 
polydispersity index. The release tests of TMZ from liposomes were performed in PBS for 51 
hours.  
 
 
1.3 Thesis Organization  
 This thesis is organized into five chapters. Chapter 1 is the Introduction, where a brief 
explanation of the motivation behind carrying out this particular project, as well as the main 
objectives for this dissertation are presented. Chapter 2, the State of the art, is a literature 
review of the following key topics: glioblastoma (GBM); TMZ; PLGA as DDS; liposomes as DDS; 
NPs already existing for TMZ. In Chapter 3, Material and Methods, the preparation and 
techniques for characterization of the nanosystems are described. In Chapter 4, Results and 
Discussion, the main experimental results and achievements are presented and discussed. 
Finally, in Chapter 5, concluding remarks and future perspectives for the continued research 
based on this dissertation project are presented.   
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2. STATE OF THE ART 
2.1 Glioblastoma 
  Glioblastoma (GBM) is a highly malignant tumour of astrocytic lineage in the central 
nervous system (CNS) and the most common glioma, accounting for 60 to 70% of all the 
gliomas2. Astrocytes, the principal glial cell in the CNS, are responsible for providing structural 
support, metabolic support to neurons such as supplying nutrients and modulating 
neurotransmitter function, maintenance and repair of the blood-brain barrier (BBB)3. The 
endothelial cells lining the capillaries in the brain are modified and prevent potentially harmful 
molecules from entering the brain4. 
Current therapies include surgery and radiotherapy as well as administration of 
chemotherapeutic drugs including Temozolomide, TMZ. The prognosis of GBM is poor; the 
median survival is approximately 12 months and less than 3% of patients survive more than 3 
years2,5. A serious constraint in the treatment of malignant gliomas is the inability to cross the 
blood brain barrier. However, with improved (targeted) drug efficacy, the overall survival rate 
may increase and provide the chance for patients to have a better quality of life. 
2.2 Temozolomide 
Temozolomide (TMZ), a chemotherapeutic agent, has demonstrated activity against 
glioblastoma and recurrent astrocytomas5–7. Adjuvant TMZ chemotherapy with radiation has 
been shown to significantly improve progression free survival and overall survival in 
glioblastoma patients, from 12.1 months to 14.6 months. 5 TMZ has the advantage of being able 
to cross the BBB8. 
Besides being a standard treatment for GBM, TMZ has been used to treat a variety of 
different neoplasms: advanced malignant neuroendocrine tumours (gastric, thymic, bronchial 
and pancreatic endocrine); low grade-gliomas; malignant melanoma; aggressive pituitary 
carcinomas; and recurrent anaplastic oligodendrogliomas 9–12 
2.2.1 Chemical Composition 
Temozolomide (TMZ) is also known as Methozolastone, TEMODAR, Temozolamide, as well 
as 85622-93-1. Its compound ID (CID) is 5394. The molecular formula is C6H6N6O2 with a 
molecular weight of 194.1 g/mol (structural formula shown in figure 1). The chemical name of 
temozolomide is 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide13. 
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Multiple nitrogen atoms in the compound were a key element to design the drug, an 
imidazotetrazine derivative, in the 1970s. .  
 
 
 
 
 
 
 
Fig1: Chemical structure of TMZ [Image obtained from 14] 
The compound is a white to light tan/light pink powder, maintaining its stability at acidic pH 
<5 and labile (readily or continually undergoing chemical, physical, or biological change or 
breakdown) at pH >7. TMZ is slightly soluble in aqueous solution (2-5mg/ml), acetone, 
acetonitrile and methanol. It is soluble in dimethyl-sulfoxide (33mg/ml) and very slightly soluble 
in ethyl acetate and ethanol (0.4-0.6 mg/ml). It has no pKa because it has no functional groups 
that can be protonated or deprotonated at pH 1-1315. Figure 2 presents the Fourier transform 
infrared spectrum of TMZ. Two strong characteristic bands are observed at 3400 cm−1 and 1610 
cm−1. The first is due to the N-H stretching mode and the second correspond to the C=C or C=N 
stretching vibration. TMZ can also be detected through UV-spectroscopy where it has a 
characteristic peak around 328nm 16,17. The characteristic UV-Vis spectroscopy peak is shown in 
Figure 3 below. 
 
                                    
 
 
 
 
 
 
Fig 2 FTIR spectrum of TMZ 18.   Fig3: UV-vis spectrum of TMZ shows characteristic peak at a  wavelength of  
              328nm. Stability of TMZ in a 10 mM buffer solution at pH 7 showing  
              absorbance of TMZ over time [image adapted from 16].  
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2.2.2 Target Site 
 
TMZ can be administered orally and intravenously. It is spontaneously hydrolyzed at 
physiologic pH to the active component 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide 
(MTIC). MTIC is then further hydrolyzed to 5-amino-imidiazole-4-carboxoamide (AIC), known 
to be an intermediate in purine and nucleic acid biosynthesis and into methylhydrazine, the 
active form responsible for alkylation. Figure 4 shows the chemical structures of TMZ, MTIC 
and AIC and how the structures are hydrolyzed to produce their respective active 
components8.  
   
  Fig. 4 Chemical Structures of TMZ, MTIC and AIC 8 
 
 
 
2.2.2 Pharmacologic Action 
Temozolomide works through the alkylation and crosslinking of DNA. This leads to the 
eventual degradation of DNA and eventual apoptosis or programmed cell death 19.   TMZ 
undergoes rapid chemical conversion in the systemic circulation and within cells at physiological 
pH to the active compound, MTIC. TMZ exhibits schedule-dependent antineoplastic activity by 
interfering with DNA replication 19 (Figure 5). 
9 
 
 
Fig 5.Temozolomide is spontaneously converted to its active form, MTIC. MITC then enters the nucleus passively and alkylates DNA 
at the O6 and N7 positions of guanine. This leads to eventual degradation of DNA and eventual apoptosis of the cell 19.   
Absorption, distribution, metabolism and excretion of TMZ throughout the body after 
administration influence the drug levels and kinetics of drug exposure to the tissues, and this 
have an impact on the performance and pharmacological activity as a therapeutic agent.  In a 
study, oral TMZ was absorbed rapidly and converted to the active substance, MTIC, and then 
into AIC. Tmax values for MTIC were 1.5 to 2 hours after a single dose, and mean Tmax values for 
AIC was at 2.5 hours.  Peak plasma concentration Cmax values for MTIC and AIC compared to TMZ 
were 2.5-4.7% and 13% respectively. The mean area under the plasma drug concentration-time 
curve (AUC) showed the body exposure to drug after administration of a dose of the drug, varied 
depending on dose. Mean AUC values ranged from 14.3-15-5 µg.hr/mL for a 100mg/m2 dose to 
176 µg.hr/mL for a 1000 mg/m2. TMZ shows low protein binding (10% to 20%) and is therefore 
not likely to interact with high protein bound agents.   
Autoradiography data shows a rapid and extensive distribution of 14C-temozolomide to all 
tissues20. The main pathway for excretion was via the kidneys, with only small amounts of 
radioactivity having been excreted via faeces or via the lungs as CO2. 20. After oral administration 
of 14C labeled TMZ, mean faecal excretion of radioactive C over 7 days was 0.8%. The total 
recovery of 14C is thought to be low due to the incorporation of AIC into the tissue purine pool. 
Following oral administration about 5-10% of the dose is recovered unaltered in urine over a 
period of 24hours, the remainder being excreted as AIC or unidentified polar metabolites 20,21.  
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2.2.4 Limitations of TMZ in treatment of GBM  
GBM is characterized by frequent chemotherapy resistance, in particular to alkylating-
based therapies such as TMZ. Resistance to chemotherapy could be either intrinsic (no 
response to therapy upfront) or acquired (no response following initial response to same 
therapy). High grade gliomas usually show both intrinsic and acquired resistance, which is 
most often due to overexpression of the DNA repair enzyme MGMT. The O6-methylguanine 
DNA methyltransferase (MGMT) gene is encoded on the long arm of chromosome 10, at loci 
10q26. O(6)- alkylguanine is the main mutagenic, carcinogenic and cytotoxic lesion in DNA.  
Tumour expression of the MGMT enzyme is an expression of the methylation status of the 
promoter region of the MGMT gene. Hypomethylated (undermethylated) promoter region 
of the MGMT in tumours, cause an overexpression of the MGMT enzyme and therefore 
show diminished sensitivity to TMZ. It has been found that approximately 60% of patients 
with newly diagnosed GBM have a very high MGMT content and thus demonstrate intrinsic 
resistance to TMZ-based chemotherapy 7. The treatment of GBM with TMZ is palliative and 
noncurative; a patient with GBM who receives surgery, radiation therapy and as well as 
adjuvant chemotherapy regardless of age will have an overall survival of 14.6 months on 
average5. 
TMZ can induce systemic toxicity including thrombocytopenia, lymphopenia, 
myselodysplasia. It was reported that 7% of patients who had to discontinue the treatment 
due to the presentation of these toxic side-effects. This number increased to 14% with 
patients who were administered TMZ after radiotherapy5.  When patients present with 
thrombocytopenia, further chemotherapy cannot be administered safely, requiring 
frequent transfusions placing patients at risk of long-term bleeding.  
TMZ, when compared with other alkylator-based chemotherapies, shows lower toxicity 
(half to a third as toxic as nitrosoureas), but still has significant toxicity that affects treatment 
and management of patients with gliomas. Thus, there remains an unmet need for a safe 
and nontoxic glioma therapy7. 
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2.3. Biomaterials already in use for Drug Delivery Systems  
The efficacy of conventional chemotherapy is limited due to the difficulty of delivering 
therapeutic drug concentrations to the target tissue or by their deleterious side-effects on 
normal tissues and organs. To overcome these restrictions, different approaches have been 
employed to attempt to use selective delivery to the affected area. The ideal solution would 
be to target the drug only to the diseased organs, tissues or cells in question.  
 Colloidal particulates, resulting from physical incorporation of the drug into a particulate 
colloidal system such as liposomes, micro-nanospheres, erythrocytes and polymeric and 
reverse micelles, can be suitable for targeted drug delivery. These colloidal particulates are 
all biocompatible and biodegradable which makes them attractive candidates for drug 
delivery systems (DDS)22.  
Biodegradable polymers and their respective copolymers are the chosen materials for 
the manufacturing of a variety of medical and pharmacological devices including DDS for 
parenteral administration for example.  DDS formed on the basis of polymer particles either 
as nanoparticles (NPs) or as microparticles 23,24. NPs as DDS have several advantages: particle 
size and surface can be engineered in order to obtain passive or active drug targeting; drugs 
can be incorporated without the occurrence of a chemical reaction; drug activity is 
preserved; different routes of administration can be used to deliver these drugs 23.  
Applying DDS in chemotherapy is an attractive option and has been studied for the last 
few decades in order to increase drug concentration at a specific site and to reduce, often 
severe, systemic toxicity23. This would allow for repeated treatment without concerns about 
the deposition of the biopolymers or biosynthetic polymers, which could reduce the 
therapeutic effects.  
 Structure, properties and applications of nanoparticles are strongly affected by 
the properties of the polymer used in their formulation. For each application and drug, one 
must evaluate the properties of the system (drug and particle) and determine the optimal 
formulation for a given drug delivery application. Polyesters based on polylactide (PLA), 
polyglycolide (PGA) polycaprolactone (PCL), and their copolymers like poly (lactic-co-glycolic 
acid)  (PLGA),  have been widely used as drug delivery systems24. Other than use for 
extended-release pharmaceuticals, PLGA and PLA have also been approved by the FDA for 
several clinical applications, such as sutures, bone plates and abdominal mesh24.  
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2.4 Liposomes as Drug Delivery Systems 
2.4.1 What are Liposomes? 
 Liposomes are vesicles made up of phospholipids. Phospholipids spontaneously form 
enclosed structures when hydrated in aqueous solutions. These vesicles, made up of one or 
more phospholipid bilayer membranes, are able to carry drugs of both hydrophilic and 
hydrophobic nature due to the amphipathic composition of phospholipids. Liposomes possess 
various properties that make them attractive candidates for DDS. Liposomes, composed of 
natural phospholipids are biologically inert, are weakly immunogenic and have low intrinsic 
toxicity.  Drugs with different lipophilicities can be encapsulated into liposomes: while strongly 
lipophilic drugs are entrapped almost completely in the bilayer, strongly hydrophilic drugs are 
located almost exclusively in the aqueous compartment and drugs with intermediate logP 
partition easily between lipid and aqueous phases, and can be found in the bilayer as well as in 
the aqueous core 25,22.  
 There are several parameters that can be used to classify liposomes: lamellarity (uni-, 
oligo-, and multi-lamellar vesicles) (figure 6), size (small, intermediate or large) and preparation 
method. Unilamellar vesicles consist of one lipid bilayer and can have diameters between 50 
and 250 nm. They contain a large aqueous core and are used to encapsulate water-soluble drugs. 
Multilamellar vesicles are composed of an onion-skin-like arrangement made up of many 
concentric lipid bilayers, having diameters between 1 and 5μm.  These multilamellar vesicles, 
have a high lipid content and can thus passively entrap lipid-soluble drugs22.  
 
 
 
 
 
 
 
 
Figure 6: Basic structures of different types of liposomes 26 
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Encapsulation of temozolomide in liposomes does not seem to have been done thus 
far, though studies of liposomal doxorubicin (Calaex) plus temozolomide have been 
described27. However, targeted drug therapy where efficient delivery of liposome-mediated 
MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells has been 
described28.  It has been shown that small-interfering RNA (siRNA)-based downregulation of 
MGMT could enhance the chemosensitivity of malignant gliomas such as GBM for TMZ. 
Notably, TMZ-resistant glioma-initiating cells with increased DNA repair and drug efflux 
capabilities could be efficiently transduced with MGMT-siRNA by using a novel liposome, 
LipoTrust ™. Thus, these transduced glioma-initiating cells could be sensitized to TMZ in both 
in vitro and in vivo tumor models28. 
 
 2.4.3 Overcoming Barriers of Conventional Drug Therapy through 
Liposome DDS   
  The main problems in drug therapy are biodistribution throughout the body and the 
targeting of specific receptors. These drawbacks can be overcome by the use of liposomal 
preparations that protect encapsulated molecules from degradation and that can passively 
target tissues or organs that have a discontinuous endothelium (e.g the liver, spleen or bone 
marrow). After intravenous administration, liposomes are quickly captured by the 
mononuclear phagocyte system (MPS) and removed from the blood circulation 29,30. This 
feature has been exploited for therapeutic purposes in order to target diseases like 
infections located within the MPS, as in the treatment of leishmaniesis with the use of anti-
parasitic and antimicrobial drugs31, and for the encapsulation of immunomodulators in 
activated macrophages to produce tumoricidal agents in cancer models. When the target 
site is not the MPS, the uptake of liposomes by macrophages and their consequent removal 
from circulation is one of the main disadvantages of using of liposomes as a DDS. MPS 
removes liposomes, by binding to opsonins such as selected serum proteins such as 
immunoglobbulins, fibronectin beta-2 glycoprotein and C-reactive protein which bind to the 
surface of liposomes22. 
  The complement system, which acts through initiating membrane lysis and enhancing 
uptake by the MPS cells (monocytes and macrophages) is also able to recognize liposomes. 
The assembly of C59b-9 complexes (membrane attack complexes, MAC) is able to produce 
lytic pores which induce the contents of liposomes to be released. On the other hand, serum 
components that inhibit the phagocytosis of pathogens, dysopsonins, have also been 
identified. Human serum albumin and IgA possess dysopsonic properties that inhibit 
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recognition and phagocytosis by the immune system. Regulation of the rate of opsonin 
clearance has been found to be due to the balance between blood opsonic proteins and 
suppressive dysopsonic proteins.  Another limitation to the stability of liposomes within 
plasma is the interaction of these with high (HDL) and low density (LDL) lipoproteins. This 
interaction causes the quick release of the encapsulated drug into the plasma 32,33.  
  Liposomal physicochemical properties such as net surface charge, hydrophobicity, size, 
fluidity, and packing of the lipid bilayers all have an impact on the kind of proteins that bind 
to them and to their overall stability34,35. It has been shown that incorporation of cholesterol 
(CHOL), allows for manipulation of the lipid bilayer through causing the phospholipids to be 
packed more tightly, which in turn reduces transfer of phospholipids to HDL36. Liposomes 
formed from phosphatidyl choline (PC) that have saturated fatty acyl chains (leading to high 
liquid crystalline transition temperature) or from sphingomyelin (SM) have been found to 
be more stable in the blood than liposomes prepared from PC with unsaturated fatty acyl 
chains37. Modulating liposome size and charge is performed in order to reduce uptake by 
the MPS. The larger the size of the liposome the more rapidly it is cleared from the blood 
circulation. The half-time of of small unilamellar vesicles (SUVs) is thus longer than that of 
multilamellar vesicles (MLVs), indicating that phagocytes can distinguish between the sizes 
of foreign particles. It was therefore deduced that the binding of opsonins to liposomes is 
dependent on liposome size, and that consequently MPS uptake was also size-dependent 22. 
 Negatively charged liposomes (with carboxyl groups) prolong half-time of the liposomes 
in the blood, while positively charged liposomes are toxic and are removed rapidly from 
circulation 38. Acidic phospholipids are recognized by scavenger receptors on the surface of 
macrophages 39. Surface charge is an important factor in complement system activation by 
liposomes. In both human and guinea-pig serum, negatively charged liposomes activate the 
complement system through the classical pathway, while positively charged liposomes 
activate it via the alternative complement pathway 40.  
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2.4.3 Functionalization of Liposomes 
Overcoming the elimination of liposomes from the blood and capture of the liposomes 
by cells of the MPS is crucial and several solutions have been developed22. The following 
paragraphs will demonstrate a few of the most common strategies to overcome the barrier 
of liposome uptake by the MPS.  
  Immunoliposomes have been developed in order to increase liposomal drug 
accumulation in the desired tissues and organs. Incorporating surface-attached ligands that 
are able to recognize and bind to cells of interest has been used to form targeted liposomes. 
Immunoglobulins (Ig) of the IgG class and their fragments are the most used targeting 
moieties for liposomes, which can be attached to liposomes without disrupting their 
integrity or the antibody properties. The IgG is either bonded covalently to the liposome 
surface or attached through hydrophobic insertion into the liposome membrane after 
modification with hydrophobic residues 41. However though there have been significant 
improvements in targeting efficacy most immunoliposomes accumulate in the liver due to 
insufficient time for the interaction between the target and targeted liposome to occur. 
Improved target accumulation can be expected if liposomes can be made to remain in the 
circulation for a longer period of time 42.  
  Several techniques have been tested to achieve long circulation of liposomes in 
vivo, through coating the liposomes with inert, biocompatible polymers such as poly-
ethylene glycol (PEG).  PEG coating forms a protective layer of the liposome surface by 
slowing down liposome recognition by opsonins and consequent clearance22. Such 
PEGylated liposomes are now being used in clinical practice22. These polymers are flexible 
allowing a small number of such polymer molecules to be grafted onto the liposome surface 
creating an impermeable layer over the liposome surface. Long-circulating liposomes have 
been shown to be dose-independent, non-saturable, have log-linear kinetics and an 
increased bioavailability.  Upon PEGylated liposomes accumulating at the target site, 
through enhanced permeability and retention effect, EPR, where molecules of certain sizes 
(typically liposomes, nanoparticles, and macromolecular drugs) accumulate in tumor tissue 
much more (due to higher vasculature and lower lymphatic drainage) than in normal tissues, 
the PEG is removed due to specific characteristics of the pathological conditions, for 
example: decreased pH in tumours22. Other molecules such as polyvinyl alcohol,  poly-N- 
vinylpyrrolidones and L-amino acid-based biodegradable lipid-conjugates have been found 
to also provide steric protection of liposomes and thus be used to produce long-circulating 
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liposomes 43–45.  However, PEGylated liposomes, previously thought to be completely 
biologically inert were found to activate the compliment system and cause certain side-
reactions to take place 46. Table 1 shows how functionalizing liposomes with specific ligands 
increases efficacy through targeting specific receptors or properties of the cell.  
 
Table 1: Examples of Ligands that have been bound to liposomes in order to increase specificity of liposomes to target 
cell 
  
Targetting 
Moiety 
Function Example Ref 
PEG-Ig or PEG 
spacer with Ig 
Allows for liposomes to be long-
circulating increasing 
bioavailability. Accumulation at 
target site.  
Anti-Her2 liposomes (breast 
cancer)  
22 
Folate  Folate receptors (FR) that are 
over-expressed in tumours. Enter 
via FR by endocytosis and 
overcome multidrug resistance; 
increases cytotixiciy 
Folate modified doxorubicin-
loaded liposomes (leukaemia; 
peritoneal tumours)  
47 48,49 
Transferrin Targets transferrin-receptor (TfR) 
on cell receptor- enters cell via 
receptor-mediated endocytosis. 
TfR overexpression in cells. 
Doxorubicin-loaded liposomes 
coupled with Tf (glioma cells) 
50 
Other ligands 
overexpressed 
in tumours 
Bind to Integrin 
(Arginylglycylaspartic,RGD); anti-
EGFR Ig to bind to bind to 
overexpressed EGFR in tumour 
cells;  mitomycin C binds to 
hyaluronan (structural part of 
extracellular matrix) 
Cancer murine models 51,52  
pH-sensitive 
molecules 
Liposomes release their contents in 
response to a decrease in pH inside 
endosome after endocytosis. 
Combination of pH sensitive 
liposomes with ligand targeting 
used for both Tf and folate-
liposomes.  
42 
 
 
2.4.4 Routes of Administration 
There are several routes of administration that are currently being explored for liposomal 
systems.  Administration of liposomes orally requires vesicles to be highly stable, and that the 
liposomes travel from the gastrointestinal tract to the blood, only beginning release when they 
are in the blood 53.  
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Liposomal aerosols were developed after liposome drying methods were established54. 
They were considered an attractive and feasible option for pulmonary drug delivery. Combined 
aerosol of liposomal paclitaxel and cyclosporin A has shown better outcomes in pulmonary 
metastases of renal-cell carcinoma in mice than each alone 55. Delivery of aerosolized liposomes 
with rifampicin presented better results in the treatment of tuberculosis 56. Nebulization has 
been suggested as a delivery mechanism for liposomal aerosols 57,5857,58. 
Another route of administration of liposomes is through skin 59. Different disease models 
have been explored as targets for topical liposomal drug delivery ranging from skin conditions 
such as eczema to arthritis and systemic disorders such as diabetes. The efficacy of local 
anesthetics was enhanced using liposomal delivery. Highly flexible liposomes known as 
transferosomes, that accompany the trans-epidermal water activity gradient in the skin have 
been proposed as DDS. Their elasticity permits the vesicles to enter intact skin and to be 
absorbed into blood circulation59. Transferosomes encapsulated with Diclofenac (a non-
steroidal anti-inflammatry drug, NSAID), was effective when tested in horses 60. Liposomes have 
been used in combination with Iontophoresis (the application of an electric current as a means 
to enhance the flux of ionic compounds through a membrane such as skin), showing favorable 
results61. 
Intravenous administration of liposomes, such as doxorubicin-encapsulated liposomes 
(mentioned earlier) has been combined with radiotherapy for cancer, to enhance therapeutic 
effect. This combination therapy showed better accumulation of liposomes in the tumour site 
and  increased necrosis of tumour tissue was observed 62.  
Liposomes administered subcutaneously have been proposed as a useful tool to target 
the lymphatic system. The liposomes are carried by lymphatic vessels to the regional lymph 
nodes where they are taken up by macrophages63. Administering biotin and avidin-bound 
liposomes allows for higher aggregation in macrophages in the lymph node 64.    
There is great intra- and interindividual variability in the pharmacokinetics (PK) and 
pharmacodynamics (PD) of liposomal drugs that complicate their application in clinical practice. 
Until the drug is released from the liposomal carrier, the PK is only dependent on the liposome. 
Two groups of factors influence PK/PD, factors associated with the physicochemical properties 
of liposomes such as size, surface charge and lipid-membrane composition and host factors such 
as age, gender, body composition and the MPS65.   
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2.3.4 New Generation Liposomes 
  Virosomes are homogeneous spherical unilamellar vesicles, assembled from lipids and 
purified virus envelope protein66.  Virosomes were originally developed for intracellular 
delivery of drugs and DNA, however, subsequently they have been used for the 
development of new vaccines. Virosomes deliver protein antigens to the immune system, 
preferentially targeting dendritic cells66–68. The only virosome to be clinically tested and 
commercially available is derived from the influenza virus66.   
  Magnetic liposomes, where both drug and a ferromagnetic material are loaded within 
the nanoparticle, have been developed. When a magnetic field is applied around the target 
site, the magnetic liposomes accumulate at a higher concentration69.  
  Cytoskeleton-specific immunoliposomes have been used in order to target specific 
tissues. Anti-cardiac myosin monoclonal antibody-bearing liposomes recognize 
cardiomyocytes with damaged plasma membranes which expose the intracellular myosin.  
This is used to deliver liposomes to hypoxic cells in myocardial infarcts to assist in repair of 
the membrane70. 
  Liposomes encapsulating human hemoglobin have been developed to enhance oxygen 
transfer and as a blood substitute71.  ATP-loaded liposomes have also been developed to 
protect cells from energy failure or to improve the energy state72,73. In photo-dynamic 
therapy, which is used for tumour ablation, liposomes are used to carry and to enhance 
photo-sensitizing agents74.  
 2.5 PLGA for Drug Delivery Systems  
 2.5.1 Physico-chemical properties of PLGA 
Poly lactic-co-glycolic acid (PLGA) is a physically strong, highly biocompatible and 
biodegradable polymer that has been studied extensively for delivery of drugs (DDS), 
proteins and other macromolecules 75.  
PLGA biodegrades through hydrolysis of its ester linkage. PLGA is considered to be one 
of the most successfully used biodegradable polymers because its hydrolysis leads to the 
metabolite monomers, lactic acid, and glycolic acid, which are easily metabolized further by 
the body via the Krebs cycle  24,76.   Hence, PLGA does not produce systemic toxicity. Figure 
7 presents the chemical structure of PLGA. The time needed for the degradation of PLGA is 
related to the ratio of monomers used in its production. The higher the amount of glycolide 
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units, the lower the time required for its degradation. However when there is a 50:50 ratio 
of monomers, degradation occurs at the fastest rate in both in vivo and in-vitro 
(approximately two months). The degradation rate can then be decreased comparatively 
when either the lactide or the glycolide units of the copolymer are increased 24. 
 
 Figure 7: Chemical Structure of PLGA polymer. The “m” component represents lactic acid and “n” component represents 
glycolic acid 24 
It is known that controlled drug release profiles are provided by changing the PLGA 
copolymer ratio which affects the crystallinity (low crystallinity and a more amorphous 
polymer leads to higher degradation rate) of PLGA. If there is a higher ratio of PGA, the 
crystallinity increases. PLGA of different molecular weights, ranging from 10 kDa to over 100 
kDa exist. Molecular weight and copolymer molar ratio influence the degradation process 
and release profile of the drug entrapped. In general, low molecular weight PLGA have faster 
degradation rates 24. Poly (lactic acid) (PLA) contains methyl groups that make it less 
hydrophilic, absorbing less water and hence copolymers with a high PLA content degrade 
more slowly than those with a higher Poly (glycolic acid) (PGA) content.  
 
Figure 8: Hydrolysis of PLGA 76 
The drug type can also be a factor that affects the degradation of the polymer. The drug 
release profile varies considerably depending on the chemical properties of the drug 77. The 
amount of drug loaded into the nanoparticle also plays a significant role in the rate of drug 
releases. A higher drug content, correlates with a larger initial burst release compared to 
those that have a lower drug content 78 
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pH has a strong influence on PLGA hydrolysis, as in vitro studies have shown that both 
alkaline and highly acidic media affect degradation of the polymer. Slightly acidic and neutral 
media however, do not show such effects79.  
 It has been hypothesized that although PLGA degrades primarily via hydrolytic degradation, 
enzymatic degradation of PLGA may also occur. However this has not yet been confirmed 
in-vivo 80,81.   
PLGA is the biodegradable polymer that has been investigated the most 82. The 
polymer is approved by the FDA and European Medicine Agency (EMA) for several drug 
delivery systems in humans and is available in different molecular weights and copolymer 
compositions1. Depending on all the factors mentioned above, the degradation time can 
vary from several months to several years 83, one of its most favorable characteristics. It is 
this has a slow rate of degradation, which governs the rate at which the loaded drug is 
released. For example, FDA approved drug formulations such as that for recombinant 
growth hormone, used in the treatment of paediatric growth hormone deficiency (GHD), 
developed in 1999, requires only one or two doses a month compared to conventional 
therapy which required multiple doses per week 82.   
 
 2.5.2 Internalization of PLGA NPs 
  PLGA NPs are internalized through fluid phase pinocytosis and also through clathrin-
mediated endocytosis. After cellular internalization (via endocytosis) the PLGA NPs undergo 
a surface charge reversal (anionic to cationic) due to the acidic pH of endo-lysosomes 
destabilization of late-endossomal membrane allowing efflux of NP and drug release84 as 
shown in figure 9.  
 
 
 
 
 
 
Figure 9: Schematic representation of NP internalization in cells and rapid release of drug from  
 endosomes85. 
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2.5.3 Synthesis of PLGA Nanoparticles 
Several methods have been devised to syntheise PLGA nanoparticles depending on the 
physico-chemical characteristics of the drug to be encapsulated. The most common is the 
emulsification- solvent evaporation technique.  
Single emulsion solvent evaporation process 
This technique is used for the encapsulation of hydrophobic drugs. It consist in dissolving 
PLGA and the drug in an organic solvent such as dichloromethane (DCM), ethyl acetate (EÄ) to 
form a single phase solution. This organic solution is then emulsified by using water containing 
a surfactant (Polysorbate 80, Polaxamer 180, Pluronic F127 etc.) to form an oil-in-water (O/W) 
emulsion.  The nanosized droplets are formed by sonication. The organic solvent is then 
evaporated and the nanoparticles collected upon centrifugation 86–88.  
 Double emulsion solvent evaporation process 
This technique is used to encapsulate hydrophilic drugs. First, the drug is dissolved in an 
aqueous phase and then added to the organic phase containing PLGA and stirred vigorously to 
produce the water-oil (W/O) emulsion. This emulsion is added to an aqueous solution containing 
a surfactant and further emulsified to form the water-oil-water (W/O/W) emulsion followed by 
sonication of the emulsion. The organic solvent is then evaporated and the nanoparticles 
collected upon centrifugation 86–88.  
In emulsion solvent evaporation techniques choice of solvent and stirring rate are crucial 
to the encapsulation efficiency and final particle size 1.  Also, different sources use different 
emulsifying agents. Polyvinyl alcohol (PVA) has been said to be used frequently to form more 
uniform NPs that are smaller in size and are easy to redisperse in aqueous medium at the end 
of the procedure 89. 
Nanoprecipitation 
Another technique nanoprecipitation or interfacial deposition method, where polymer 
and drug are dissolved in an organic solvent such as acetone and added dropwise into water or 
allowed to dialize out into the aqueous phase the organic solvent is evaporated and the 
nanoparticles collected after centrifugation. The advantages of this technique is that it allows 
for both hydrophilic and hydrophobic molecules to be encapsulated and is a relatively simple 
technique90. 
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2.5.4 Application of PLGA as DDS: What is already available? 
PLGA NPs hold huge potential in applications combining targeting, imaging, diagnostics and 
therapy 91. Conjugation, where drug remains adsorbed to surface, as well as encapsulation of drugs 
in PLGA systems decreases the limitations of the drugs such as short circulation half-life and non-site 
specific targeting. The latter leads to undesirable systemic side effects, particularly those of the 
highly toxic compounds used for the treatment of malignant disease. PLGA DDS increase the in-vivo 
circulation time substantially and also reduce endocytic cellular uptake 92.  
Table 2: Summary of Examples of DDS PLGA systems developed mostly in the areas of cancer and brain 
 disease.  
 DDS (kind of NP) Functionalization Application Studies 
 PLGA- (Doxorubicin) cLABL A549 lung epithelial cells  (cancer)  
In-vitro 
93 
 
 
 
PLGA- (Paclitaxel) None but coated 
Cremophor EL 
Stabilizer 
Wide range of cancers (brest, lung, 
Ovary and leukaemia) clinical use 
94 
 PLGA- (Paclitaxel) AS1411 DNA 
aptamer which binds 
to nucleolin in 
plasma membrane 
Anti-glioma drug delivery  
In-vivo   
95 
 PLGA- (Paclitaxel) RGD-PEG Targets αvβ3  96 
CANCER PLGA- (Doxorubicin) PEG Anti-tumoural;  In-vitro 97,98 
  PLGA-(Doxorubicin)- Au Au As the PLGA NPs biodegraded, DOX 
was released, and heat was 
locally generated upon near-
infrared (NIR) irradiation due to 
NIR resonance of DOX-loaded-Au 
NPs.   
99 
 PLGA- (Paclitaxel) 
 
Folate Targets folate receptors in cancer 
Cells; in-vivo, in-vitro 
 
100 
 PLGA- (Doxorubicin) 
 
 
 
Folate- Vitamin E Targets folate receptors and 
improves drug permeability across 
cell membranes 
In-vivo, in-vitro  
101 
INFLAMMATION PLGA-(Dexamethasone) - Occular delivery for uveitis and other 
eye infections. in-vitro  
102 
 PLGA-(superoxide 
dismutase) 
- Increases BBB permeability, more 
efficient against oxidative stress in 
cerebral ischemia, restoration of 
neurological functions after stroke.  
Preclinical (mice) 
103 
CEREBRAL DISEASES PLGA (urocortin)  Lactoferrin  Binds to lf receptors in the BBB 
facilitating its passage through it. 
Used for Parkinson disease; 
Preclinical 
104 
 PLGA-(loperamide) Simil-opioid peptide, 
sialic acid 
Allows anti-nociceptive drug to cross 
BBB. Remains in brain parenchyma. 
Preclinical  
104–107 
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2.5.5 PLGA DDS developed for TMZ 
 TMZ is the drug of choice used in the treatment of GBM. Due to its very short half-life of 
1.8hrs and adherence of proteins to its surface, repeated administration of the drug is 
required. Systemic side-effects as well as lack of site-specificity, meaning that the amount 
of drug reaching the tumour site is limited, are further drawbacks. 
Recently, a variety of approaches have been tested and applied in order to enhance the 
loading of TMZ into materials such as PLGA. PLGA has been used as a microparticle for 
coating TMZ 108,109. Zhang et al 2012 encapsulated TMZ with hydroxyapatite nanocrystals 
(nHA) under different morphological conditions, rod-shaped and spherical, to test 
differences in loading capacities and the efficacy of drug release. The in-vitro drug release 
assay showed that TMZ/PLGA/nHA microspheres have a much slower burst release rate of 
TMZ compared to TMZ/PLGA due to the nHA, which plays an important role in the process 
of TMZ controlled release 108. Moreover, their study also showed that the use of nHA as an 
additive helped both in the release of TMZ from microspheres to occur, and in inhibiting 
glioma growth and invasion when tested in vitro with the U87 glioma cell line. Ultimately, 
the TMZ/PLGA/nHA microspheres have shown the best performance in TMZ controlled 
release as well as in inhibition of cell viability. Therefore TMZ/PLGA/nHA microspheres show 
potential as drug delivery carriers for glioma therapy 108. However, there is an important 
limitation of this DDS, as the microspheres are approximately 60μm in diameter, an 
extremely large size for crossing the BBB. It is known that particles capable of crossing the 
BBB and thus entering the brain must be smaller than 200nm 110. The study also shows high 
encapsulation efficiencies, defined as the percentage of the actual mass of drug 
encapsulated in the polymeric carrier in relation to the initial amount of drug loaded, (EE% 
>80%) with a very high initial burst rate even though the nHA decreased it significantly. One 
may assume that a lot of the TMZ was adsorbed on the surface of the microsphere.  
Zhang & Gao studied TMZ-loaded PLGA microparticles and their antitumour effects 
against Glioma C6 cancer cells109. The single emulsion solvent evaporation technique was 
used, using dichloromethane as the organic phase and PVA as the emulsifying agent 
(saturated with TMZ beforehand in addition to adding TMZ to the organic phase). 
Parameters investigated included different polymer/solvent ratios (W/V%) ranging from 5 
to 13.33 as well as different stirring rates of the emulsion (400, 600 and 800 rpm), and 
different TMZ:PLGA mass ratio (5%-40%). EE% was shown to be higher using lower TMZ: 
PLGA ratios and microparticle size was approximately 60μm in all experiments. Higher 
stirring rate correlated with smaller particle size. Though there was a high initial burst of 
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TMZ in the first day, results showed sustained release over 35 days. Cytotoxicity results 
showed that TMZ-loaded PLGA decreases cell viability percentage significantly in 
comparison to PLGA alone, but results for cytotoxicity studies with TMZ alone are not 
presented, which is crucial for assessing the efficacy of the system.  
Jain et al. studied the cytotoxicity of temozolomide loaded into PLGA nanoparticles111. 
In contrast to the two studies mentioned above the NPs of 150-160nm  were developed 
using the solvent diffusion method (a modification of the solvent-emulsion evaporation 
method 111) using acetonitrile, a partially miscible organic solvent and a TMZ:PLGA mass ratio 
of 60% and zeta potential of the NPs was around -20mV. 30% of the loaded TMZ was 
released within the first 2hours but there was sustained release of the drug over the 
following 120 hours. The IC50 for the pure drug was only concentration dependent (at 72 h 
and 96 h IC50 was 150μg/mL) whereas for the encapsulated drug NP the IC50 was both 
concentration and time dependent due to variations in release rates of the drug at different 
time-points (at 72 h and 96 h IC50 was 200μg/mL and 150μg/mL). Other tests: cell motility, 
clonogenic potential, observation of changes in cellular morphology upon TMZ and PLGA NP 
treatment, flow cytometry and immunofluorescence to visualize internalization were 
performed to further prove the efficacy of the system. The latter two experiments, showed 
higher uptake of TMZ/PLGA NPs into the cells in comparison to FITC a hydrophilic molecule, 
concluding that the uptake of a hydrophilic or amphipathic molecule (TMZ) would be 
enhanced by the use of PLGA 110.   
Although the study by Jain et al. shows promising results, it would however be 
interesting to know how the IC50 varied at a wider range of time-points. Also, they only test 
their DDS on one glioma cell line. Testing this formulation on both cancer cells and normal 
astrocytic cells because since these particles are not targeted, may show very different 
results in non-neoplastic astrocytic cell lines (due to differences in morphology and 
epigenetic profile), and therefore testing cytotoxicity in these cells is crucial before 
proceeding to in-vivo models. Also, because Jain et al, use a relatively high TMZ:PLGA mass 
ratio, it would be of interest to test a range of these to see which is more effective in terms 
of EE% and differences in size of particle as well as zeta potential and polydispersity. Another 
aspect which could be explored is the stability of the NPs over time as the zeta potential of 
approximately -20 mV and flocculation of the molecules could occur over time if the NPs are 
stored for a longer period of time (more than 5 days). Hence further studies to develop TMZ 
loaded PLGA nanoparticles should be undertaken to both corroborate with the few available 
studies and to try to improve the efficacy of the system.  
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3.  MATERIALS AND METHODS 
3.1 TMZ Stability Tests  
 TMZ, Selleckchem (Munich, Germany), dissolved in PBS (solubility 0.33 mg/mL) at 10 
μg/mL and UV-spectrum  measured at hourly intervals over 36 hours at 22 °C and 37 °C and at 
pH 7 through spectrophotometry. After acidifying a 10 μg/mL to a pH of 5.6 with 0.02 M HCl 
solution, and its stability measured over 36 hours again. pH was measured with an H1 110 series 
pH meter (Hanna® Instruments, USA) and UV-vis spectrum was measured with BioTek® Synergy 
2 high-performance multi-mode plate reader. 
 A TMZ solution at 10 μg/mL at pH 7.24 was used and increased pH was achieved by the 
addition of 0.02M NaOH solution. Solutions at pH 11.2, pH 11.9 and pH 12.3 were measured. 
 Measurements were taken at room temperature using spectrophotometry with the 
BioTek® Synergy 2 high-performance multi-mode plate reader at 22 °C in triplicate.  
 The stability test was also conducted with the same materials but at differing 
temperatures: 22 °C (room temperature) and 37 °C (physiological body temperature).  
 
 
3.2 TMZ Solubility in Different Solvents  
 TMZ is an amphiphilic molecule according to the literature15,18. To study the solubility, 
TMZ was dissolved in an array of different polar and organic solvents:  water, acetone, 
chloroform, ethyl acetate, dichloromethane and dimethyl sulfoxide: all at 10 μg/mL, 
concentrations much below their saturation concentration. Each solution was measured in 
triplicate using the UV-1700 PharmaSpec UV-Vis spectrophotometer from Shimadzu (Japan).  
 
 
3.3 TMZ Calibration Curve 
 To produce a linear calibration curve of TMZ dissolved in PBS, solutions were prepared 
at 0, 2, 5, 10 and 20 μg/mL (equivalent to 0, 10.3, 25.8, 51.5, 103 μM). UV-spectrum absorbance 
at wavelengths 255 nm-266 nm (MTIC/AIC) and 328 nm (TMZ) was measured and recorded in 
triplicate and two calibration lines were set for each respective wavelength. Since 
spectrophotometry was used with both BioTek® Synergy 2 high-performance multi-mode plate 
reader and UV-1700 PharmaSpec UV-Vis spectrophotometer from Shimadzu (Japan), two 
separate calibration curves were obtained to take into consideration differences in sensitivity of 
the devices (Appendix A1 and A2).  
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 To produce liposomes, TMZ dissolved in PBS was left overnight to transform completely 
into its degradation products that have only one peak at the 255-266 nm region when measured 
by spectrophotometry. It was decided that this would simplify quantification of the drug for 
more prolonged experiments involving nanoparticles such as the release experiments (used for 
TMZ-loaded liposomes). Therefore all experiments for liposomes were used with the 
degradation products of TMZ, and quantified with a calibration curve produced with a range of 
concentrations from 0, 5, 10, 15, 20, 30, 40, 50 μM, latter is quantity of drug required to be 
encapsulated in liposomes, (equivalent to 0, 0.97, 1.94, 2.91, 3.88, 5.82, 7.77 and 9.71 μg/mL). 
UV-1700 PharmaSpec UV-Vis spectrophotometer was used to obtain these measurements 
(Appendix A3).  
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3.4 Nanoparticle Production  
3.4.1 Materials for Nanoparticle Preparation 
 For PLGA nanoparticle preparation, a solution of 1%(w/v) Pluronic F127 was prepared 
using Pluronic® F127 purchased from Sigma–Aldrich (St. Louis, Mo., U.S.A). PLGA Resomer® 
RG503H (50:50; MW = 24.000 – 38.000) and ethyl acetate were also obtained from Sigma–
Aldrich (St. Louis, Mo., U.S.A). TMZ from Selleckchem (Munich, Germany). Dimethylsulfoxide 
(DMSO) was purchased from Sigma-Aldrich (Germany). Deionized ultrapure water was used to 
prepare Pluronic F127 solutions. 
 For liposome production, lipids were purchased from Avanti Polar Lipids: DSPC (1,2-
distearoyl-sn-glycero-3-phosphocholine, MW 790.145), Chol (cholesterol ovine wool, MW 
386.65), DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] ammonium salt), MW 2790.49). Each of these reagents were 
dissolved in chloroform. TMZ solution was prepared in Phosphate buffered saline (PBS) at 
different concentrations. PBS solution was prepared in deionized ultrapure water (Milli-Q 
Academic, Millipore, France).   
 
3.4.2 PLGA NPs: Method of Preparation 
 To synthesize PLGA NPs, the single-emulsion solvent evaporation technique was used80-
88. A 70 μL solution of 142.86mg/mL Resomer® RG503H of PLGA in ethyl acetate (10 mg), was 
prepared, and for encapsulation purpose a 30 μL solution of 16.67 mg/mL and 33.33 mg/mL (0.5 
mg and 1 mg respectively) of TMZ was added to DMSO. The suitable masses of TMZ, PLGA 
polymer and pluronic F127 were weighed in a NewClassic MS Analytical Balance from Mettler 
Toledo (Switzerland). 
200 μL of an aqueous solution of 1% (w/v) pluronic F127 was added dropwise to the organic 
phase (PLGA and TMZ dissolved in ethyl acetate). The mixture was then vortexed (Genius 3, 
ika®vortex, Germany) for 30 seconds and emulsified by sonication in a beaker with ice using 
Ultrasonic cleaner (VWRTM, Malaysia) for 5 minutes at 45 kHz.  
After emulsification, the mixture was poured rapidly into 2.5 mL of 0.1% (w/v) pluronic F127 and 
stirred (800 rpm) at room temperature for 3 hours, to completely evaporate the organic solvents 
(DMSO and ethyl acetate), using a magnetic stirrer. It is of utmost importance that this step is 
completed very quickly in order to avoid PLGA NP aggregation before being stabilized by the 
surfactant. Evaporation took place in a flow chamber Captair®bio from Erlab (Barcelona, Spain).  
 The suspension was then filtered with Millex-GP Filter Units (0.2 μm, polyethersulfone) 
(Millipore Express, Ireland) and incubated overnight at 4°C to prevent NPs from aggregating and 
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to increase their stability. The NPs were collected by centrifugation (14500 rpm, 30 min) with 
MiniSpin®plus Eppendorf, Germany). The resulting pellet of NPs was re-suspended in 1 mL of 
ultrapure water and stored for analysis. The supernatant was also saved for quantification 
purposes (i.e- encapsulation efficiency). The method is seen in figure 10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10: PLGA NP production method.  
 
Modifications to the Method 
 
 The method was carried out as above but substituting the surfactant pluronic F127 with 
polysorbate 80 obtained from Sigma-Aldrich (St. Louis, Mo., U.S.A) in the same (w/v) 
percentages as described above for pluornic F127.   
 
 The method was also carried out as above but was produced with 0.5 mg of TMZ instead 
of 1 mg (produced at half PLGA/TMZ loading percentage).  
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3.4.3 Liposomes: Method of Preparation 
 
 To prepare the liposomes, the lipid film hydration method was used. DSPC, Chol and 
DSPE-PEG2000 were mixed in a molar ratio of 52:45:3 into a glass flask. The chloroform solvent 
was evaporated by drying with a stream of nitrogen gas while rotating the flask so as to form a 
lipid film. The flask was left in vacuum overnight to ensure that all the chloroform evaporated. 
The lipid film was hydrated by adding PBS or PBS/TMZ (for liposomes alone or liposomes with 
TMZ respectively) to obtain a final lipid concentration of 0.8 mM. Ratio of TMZ to lipids was 1:16.  
The mixture was then vortexed for 15 min to obtain MLVs. To form LUVs, the suspension was 
then treated to 10 cycles of freezing and thawing followed by extrusion 11 times through a 
polycarbonate filter of 200 nm. In order to measure the efficiency of encapsulation, a PD-Midi 
Trap G25 (GE Healthcare) column was used to separate the encapsulated TMZ from free TMZ 
molecules, eluting only the liposomes. To quantify the amount of TMZ inside the liposomes, the 
nanoparticles were burst with both ethanol and sodium dodecyl sulphate (SDS) purchased from 
Sigma-Aldrich (Germany), in a 25:75 (v/v) proportion. Figure 11 shows the method step-by-step.  
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Fig 11: Liposome production steps: a) Lipid mixture in organic chloroform (DSPC, cholesterol, PEG);  
b)drying  with stream of nitrogen gas; c)hydration with  PBS or TMZ/PBS solution and d) vortexing; d) 
freeze-thaw cycles and extrusion; and e) separation of non-encapsulated TMZ from encapsulated TMZ 
NPs through desalting column [image adapted from 112].  
 
3.5 Nanoparticle Characterization   
 
 For both PLGA NPs and liposome NPs, the size, polydisperisty index and zeta potential 
were measured using the ZetaSizer NanoZS, Malvern Instruments (Worcestershire, UK). 
 
3.5.1 Dynamic light scattering technique: size and polydispersity 
 
  DLS is a technique used to characterize particles, emulsions or molecules which are 
either dispersed or dissolved in a liquid. The Brownian motion of particles or molecules in 
suspension causes scattering of laser light at different strengths. By analyzing these changes in 
intensity, the velocity of the Brownian motion and hence particle size can be determined 
through the Stokes-Einstein relationship113. Particle size is given in terms of hydrodynamic 
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radius. The (d(H)) is the diameter of a sphere that has the same translational diffusion coefficient 
as the particle. It is a hypothetical sphere that moves identically as the particle that is being 
measured.  
 [1] 
  
Where: D is the diffusion coefficient; η is viscosity in the medium; k is the Boltzmann's constant; 
and T is the absolute temperature. Brownian diffusion depends on the following parameters: 
temperature, viscosity and size of the NP. The higher the temperature, the faster the movement; 
the higher the viscosity, the slower the movement and if nanoparticles increase in size 
movement is slower114,115.  
 To measure NP average size (in both liposomes and PLGA NPs) the measurements were 
performed using disposable cuvettes obtained from Sarstedt (Germany) and using PBS and 
water as the dispersant medium. Triplicate measurements were made and for each 
measurement, 12 runs were performed at 25°C.  
 The Polydispersity Index (PdI) is a measure of the width of the particle size distribution. 
The formula for Polydispersity is  𝑃𝑑𝐼 = (𝜎/ 𝑑)², where the polydispersity (PdI) = the square of 
the standard deviation (𝜎) / mean diameter (𝑑) 116. Polydispersity indices lower than 0.1 are 
typically referred to as "monodisperse". DLS also measured PdI when measurements for NP 
average size were made.  DLS was measured on the day of NP production as well as over time 
to look out for changes in size and polydisperisty.  
  
3.5.2 Zeta Potential through Laser Doppler Velocimetry 
 
 Laser Doppler Velocimetry (LDV) also called Laser Doppler Electrophoresis (LDE) allows 
the zeta potential to be determined through obtaining the value for electrophoretic mobility 
and then applying a mathematical model117. 
  Ions in proximity to the surface of the particle will be strongly bound while ions that are 
further away will be lightly bound forming what is called a diffuse layer. Within the diffuse layer 
there is a boundary and any ions inside this boundary will move with the particle when it moves 
in the liquid; but any ions outside the boundary will stay where they are – this boundary is called 
the Slipping plane.  A potential exists between the particle surface and the dispersing liquid 
which varies according to the distance from the particle surface – this potential at the slipping 
plane is called the zeta potential (ζ-potential or ZP). LDV measures the velocity of a particle in a 
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liquid when an electrical field is applied. The applied electric field causes the particle to move in 
relation to a stationary liquid at a constant velocity. The ratio of the velocity to the electric field, 
E, is the electrophoretic mobility, μ.  The mobility is converted into zeta potential, ζ, using the 
Smoluchowski equation:   
 
   [2] 
 where η is the viscosity of the suspension, D is the dielectric constant of the solution 
and μ is the electrophoretic mobility of particles (micrometer/s per volt/cm)118. 
 
  The value of the zeta potential gives an indication of the stability of the colloidal system. 
If all the particles in suspension have a large negative or positive zeta potential then they will 
tend to repel each other and there is no tendency to flocculate. On the other hand, if the 
particles have low zeta potential values then there is no force to prevent the particles coming 
together and flocculating117. 
  
 ZetaSizer used to measure the zeta potential of the NPs in suspension. Capillary cells 
from Malvern (Wostershire, UK) were used and the dispersant was both water and PBS. Each 
NP suspension was measured in triplicate, each measurement having had 12 runs. Zeta potential 
was measured on the day of NP production and then later measured over time to see if any 
changes in ZP value were observed.  
 
 
3.5.3  Encapsulation Efficiency (EE%) of PLGA NPs 
 
 To quantify the amount of TMZ encapsulated in the NPs, the supernatant collected after 
the centrifugation was diluted 10x and UV-Vis spectrum of the sample was measured, and 
concentration of unloaded TMZ was calculated according to the calibration curve. The EE% was 
calculated through the following formula: 
 
𝑬𝑬%  =
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑻𝑴𝒁 − 𝑼𝒏𝒍𝒐𝒂𝒅𝒆𝒅 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑻𝑴𝒁
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑻𝑴𝒁 
 𝑋 100 
            [3] 
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3.5.4 Encapsulation Efficiency (EE%) of Liposomes 
 
  The drug quantified upon bursting with sodium dodecyl sulfate (SDS), showed a peak in 
the characteristic UV-Vis region, indicative of drug entrapment. To obtain an approximate 
concentration of how much drug was present upon bursting of the liposome, another 
calibration curve was made for the degradation products alone.  
 
 The following formula was used to calculate the encapsulation efficiency: 
 
𝐸𝐸% =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛𝑠𝑖𝑑𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 
 𝑋 100 
            [4] 
3.6 Release Study of TMZ-loaded Liposomes 
TMZ-loaded liposomes were used for drug release experiment by using a dialysis membrane 
(Float-A-Lyzer G2, CE, 100 KDa, SpectrumLabs). The drug alone was used as a control in one 
membrane and the drug encapsulated in the liposomes was used in another membrane. The 
membranes were washed in ultrapure water for 12 hours before being used and equilibrated 
with buffer 1 hour before the dialysis with PBS buffer as the receiving phase. A volume of 2.5 mL 
from the liposomes and TMZ suspensions was added to their respective membrane and the 
outside space was filled with 2.5 mL of buffer. The dialysis membrane was kept in continuous 
stirring at 200 rpm at 37 °C to simulate physiological conditions. Samples were collected from 
the outside medium over and the quantity of released TMZ was determined by 
spectrophotometry (UV-1700 PharmaSpec UV-Vis spectrophotometer)). It is to be noted that 
encapsulated drug was left to transform into its degradation products before liposome 
production and therefore quantified drug is actually TMZ degradation products (MTIC/AIC) and 
not TMZ. The percentage of TMZ degradation products released at each time was then 
calculated with the following equation:  
 
𝐷𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑎𝑡 𝑡𝑖𝑚𝑒, 𝑇 (%) =
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑡 𝑇
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑑𝑖𝑎𝑙𝑦𝑠𝑒𝑑 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 
X 100 
           [5] 
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4. RESULTS AND DISCUSSION 
 
4.1 UV-Vis absorption spectrum for TMZ 
 The graph below (Figure 12) shows the absorption spectrum for TMZ when dissolved in 
water (10 μg/mL) at pH 6.3. The absorption peak for TMZ was found to be at 328 nm. Another 
peak, observed between 255 nm and 266 nm, which is the absorption peak for the active 
degradation products of TMZ hydrolysis (MTIC and AIC).  
 
Figure 12: TMZ UV-vis absorption spectrum at pH 6.3 
 
 TMZ was dissolved in an array of different solvents:  water, acetone, chloroform, ethyl 
acetate, dichloromethane and dimethyl sulfoxide and concentrations much below their 
saturation concentration. All UV-vis results showed similar absorption spectra showing that the 
solvent did not affect TMZ’s absorbance.  
Although the saturation concentration for TMZ in different solvents varies, TMZ absorbance 
spectrum was measured at a very low concentration (10 μg/mL), perhaps explaining why the 
absorbance values do not correlate with the solubility values. However, all showed the 
characteristic peak around 328 nm showing that these solvents did not alter the TMZ. Results 
are shown in Table 3. 
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Table 3: Dissolving TMZ in organic and inorganic solvents 
 
4.2 TMZ stability at different pHs and temperatures 
 TMZ dissolved in PBS (solubility 0.33 mg/mL) at 10 μg/mL uv-spectrum was measured at 
hourly intervals over 36 hours at 22 °C (Figure 13a) and 37 °C (Figure 13b). The characteristic 
peak of TMZ at 328 nm (orange) loses its intensity from 0.4 to 0.1 in 10 hours in both cases. And 
another peak, at 266 nm increases in the same timeframe from around 0.3 to 0.5. We can 
conclude that at pH 7 at both these temperatures, TMZ is rapidly being converted into its active 
form over these first 10 hours. Thus the growing peak at 266 m represents the peak for 
MTIC/AIC.  
 After acidifying the same solution, concentration 10 μg/mL, to a pH of 5.6  (figure 13c) 
no significant change was found over a 36 hour period meaning that TMZ does not undergo 
chemical change to its active alkylating form (MTIC and then AIC) over this time-frame, and is 
stable.   
 
 
 
 
 
 
 
Figure 13a): TMZ stability at 22°C at pH 7 (PBS) 
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 Figure 14 shows TMZ at pH 7.2 as well as at increasing pHs, where the characteristic 
peak for TMZ is present at 328 nm. At pH 11.2 though there is still some TMZ present at 328 nm, 
the concentration has decreased due to the decrease in absorbance and the quantity of 
degradation products (around 270) increases drastically. At pH 11.9 and pH 12.3 TMZ has 
completely degraded as there is no visible peak at 328 nm. This experiment was performed at 
room temperature (approximately 22 °C). This shows clearly that TMZ is unstable at basic pH 
and changes conformation immediately after the solution is made basic. 
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Figure 13b): TMZ stability at 37°C at pH 7 (PBS) 
Figure 13c): TMZ stability at 37°C at pH 5.6 (PBS) 
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4.3 Liposome Production and Characterization 
 Figure 15 shows liposomes at 0 hours after production (blue), as well as after 36 hours, 
liposomes alone (grey). Liposomes were stored at room temperature for 36 hours and re-read 
through spectroscopy after this time-period. The liposome sample at different time points, 
showed a very similar UV-vis spectrum curve before and after 36 hours, conferring good stability 
over this time period under these conditions. 
 
Figure 15: Liposomes after production at hour 0 and 36 hours later. 
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Figure 14: TMZ stability at basic pH  
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 Table 4 shows liposomes that were produced unloaded (alone) and loaded with TMZ. 
The size of the liposomes is slightly lower than 200 nm, an ideal size to pass the BBB. The 
differences in size and in ζ–potential for liposomes and alone and with TMZ were not statistically 
significant. 
  
 
 
Table 4: Size and ζ-potential of TMZ-loaded and unloaded liposomes  
 
  
 
 
 
 
 
4.3.1 Liposome Stability at different pH 
 Due to TMZ decomposition into its degradation products (MTIC/AIC) when the 
liposomes were being prepared at pH 7.4 in PBS; liposomal size, ζ–potential and PdI were tested 
as pH of the liposome solution was decreased gradually, to see if the liposomes maintained 
stability at an acidic pH.  
 Liposomes showed to maintain a stable size (approximately 200 nm), ζ-potential (close 
to 0), and a relatively constant PdI (between 0,1 and 0,2) until pH 6. At pH values below this: the 
average liposome size decreased; the PdI increased significantly to around 0.7, indicative of high 
polydispersity and therefore a non-uniform liposome size sample; from pH of below 6 zeta-
potential started to become significantly more positive. This set of results showed that 
liposomes appeared to maintain its size, ζ-potential and PdI close to that of liposomes at pH 7.4 
(pH of PBS) until it reached a pH of around 6, after which inconsistency was observed.  
 Liposomes stored since the day of manufacture at pH 6.1 over a 5-day period showed 
that liposomes did not maintain stability. The size increased from less than 188 nm to over 400 
nm, indicating flocculation of the particles. The ZP, and PdI however maintained relative 
stability. The aggregation of liposomes however is undesirable and thus despite TMZ 
maintaining stability at this pH, the liposomes do not, meaning that liposomes cannot be 
produced at pH below 7.   
       
 Size (nm) ζ-potential (mV) 
Liposome alone   196±4 -2±2 
TMZ-loaded liposome  197±6 -2±1 
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4.3.2 TMZ-Loaded Liposome Production 
  Figure 16 shows that during liposome production, the characteristic UV-Vis 
spectrum peak for TMZ is not present (328 nm) whereas the peak for the degradation products, 
MTIC and AIC (255-266 nm) is. This is because the TMZ solution was previously left to degrade 
until total degradation so that only one peak as opposed to two appeared, making it easier to 
quantify. Therefore, quantification was obtained only from the 255-266 nm peak values.  
 
Figure 16: Liposome production: degradation products alone before encapsulation (blue), liposome after being 
synthesized (yellow), and degradation products released after bursting liposome (red). 
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TMZ solution alone prior to hydration (blue line), synthesized liposomes (yellow) and 
drug released after bursting is shown in figure 16. The TMZ quantified upon bursting with sodium 
dodecyl sulfate (SDS), showed a peak in the characteristic 255-266nm region (dark green line), 
indicative of drug entrapment. To obtain an approximate concentration of how much drug was 
present upon bursting of the liposome, another calibration was made for the degradation 
products alone.  
 
4.3.3 Encapsulation Efficiency of Liposomes NPs  
 According to the calibration curve of the degradation products of TMZ (Appendix A3), 
the encapsulation efficiency was calculated and was between 45 and 55%.  
 
 
4.3.4 Release Study of TMZ-loaded liposomes 
 Figure 17 shows the results of the release experiments performed on TMZ-loaded 
liposomes and also with the TMZ alone control. The release experiments were stopped at 51 
hours after reaching 50% of the total of TMZ encapsulated in TMZ-loaded liposomes versus the 
98% observed for the TMZ solution. 
 
Figure 17: Release of TMZ from TMZ-loaded liposomes (green) and TMZ alone in solution (blue) 
 
 These results clearly show that the release in TMZ from liposomes is much slower and 
sustained compared to the drug alone that has an initial “burst” during the first 10 hours. This is 
desired property for the nanocarrier being developed as drugs that have a more prolonged 
release require less frequent drug administration.  
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4.4 PLGA NP Production and Characterization 
 
 Dissolving TMZ (initial mass measured 0.05 mg) in ethyl acetate (EA) to test its stability 
over time by measuring UV-Vis spectrum over a period of 9 hours. By hour 8 TMZ starts to 
degrade rapidly (Figure 18). 
 
 
Figure 18: stability of TMZ dissolved in ethyl acetate at 37 °C  
 
 The solubility of TMZ in EA is too low to permit use in the experiment; 1mg TMZ failed 
to dissolve in 2 mL of EA. Therefore subsequent dilutions to obtain desired concentration of 10 
μg/mL were required in order to obtain a characteristic UV-vis peak.  
 As stated previously in the materials and methods chapter an alteration to the 
conventional protocol of single-emulsion evaporation technique (where organic solvent is only 
composed of EA) had to be altered because 1 mg of TMZ Is insoluble in 100 μL of EA. The protocol 
was altered so that 1 mg of TMZ, previously dissolved in 30 μL of DMSO (in which it is highly 
soluble) was then mixed with 70 μL 0f EA to form an organic phase in this way.  
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4.4.1 Unloaded PLGA NP Stability over Time 
 The unloaded PLGA NPs were measured over a period of 14 days to see whether these 
values maintained, indicating stability of the NPs.  
 
Table 5: Stability of unloaded PLGA NPs over a two week period   
 size 
(nm) 
PdI ZP (mV) 
day 1 177± 5  0,08 ± 
0,02 
-31 ± 3 
day 2 176± 4 0,06± 
0,03 
-31± 2 
day 7 179± 4 0,06± 
0,03 
-31± 3 
day 14 183± 6 0,05± 
0,03 
-29 ± 3 
 
 PdI remained under 0.1 showing a good degree of monodisperse sample population and 
the ZP remained close to -30 mV perhaps explaining how the average size was maintained and 
the PdI continued below 0.1. A negative ζ-potential shows that this value (demonstrating the 
electrical potential in the diffuse layer) was negative enough to cause particles to repel each 
other, thus avoiding flocculation over the two week period over which they were measured.  
 
4.4.2 TMZ-loaded PLGA NPs 
  
 Table 6 shows the size, ζ-potential and PdI of the unloaded (PLGA alone) as well as TMZ-
loaded PLGA nanoparticles formed through the modified single-emulsion solvent evaporation 
technique. For the unloaded PLGA NPs, the size at 177 nm is a good size as it is small enough to 
eventually cross the BBB. The PdI is below 0.1 showing that it is considered a mono-disperse 
sample of PLGA nanoparticles. The zeta-potential, at -31 mV shows potential stability and a 
reduced possibility of flocculation occurring. With the TMZ-loaded PLGA particles, the size was 
similar to that of PLGA alone (176 nm), and PdI around 0.1 are good indicators as above. 
However in contrast, the ζ-potential decreased to -2 mV, confirming the encapsulation of TMZ. 
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However, one can note that the ZP is very close to zero compared to the ZP of the unloaded 
PLGA nanoparticles (where ZP was approximately -30 mV). This can be due to TMZ being 
adsorbed at the surface of the nanoparticles, causing the charge to become more positive.  
 
 
Table6: Size, zeta-potential and polydispersity of alone (unloaded) and TMZ-loaded PLGA nanoparticles 
NP PLGA 
alone  
TMZ-loaded 
PLGA 
Size (nm)     177 ± 5 176 ± 7  
ζ-
potential 
(mV) 
-31 ± 3  -2 ± 4  
PdI 0,08 ± 
0,02 
0,11 ± 0,03 
 
 
The resulting supernatant collected upon centrifugation was diluted 10x and measured in order 
to get an approximation of the EE% according to the calibration curve presented in appendix A1.  
 
Figure 19: TMZ-loaded PLGA NP supernatant UV-Vis spectrum  
  
 Figure 19 shows the TMZ and its respective degradation products that were present in 
the supernatant upon centrifugation of the prepared nanoparticles. The solution was diluted 
10x to obtain a quantifiable spectrophotometric analysis (where absorption peak is below 1). 
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 For calculating the encapsulation efficiency (EE%), one must do indirectly by measuring 
how much was not encapsulated, i.e. what remained in the supernatant after centrifugation of 
the resulting NP pellet.  
 The EE% was approximately 84% according to the calibration curve for TMZ and its 
degradation products (Appendix A1). 
 
 
4.4.3 TMZ-Loaded PLGA NP Stability over Time     
 Results from performing Dynamic Light Scattering and Laser Doppler Velocimetry are 
presented in Table 7. One can see that the size of the TMZ-loaded nanoparticles increased more 
than four-fold in a four day period indicating NP aggregation. This is most probably due to the 
low ZP (-3.66 and -3.90) compared to the unloaded PLGA particles that had a zeta potential of 
around -30 mV which correlated with unloaded PLGA particles maintaining their size.  Therefore 
one can conclude that this technique was not successful in producing stable TMZ-loaded 
nanoparticles.  
 Firstly, it is highly likely that the NPs did not contain TMZ. And that the TMZ molecules 
must have coated the surface, causing the decrease in ZP. A hypothesis for little or no 
entrapment is that TMZ may have remained in the aqueous phase. The TMZ although dissolved 
before-hand in DMSO, was then added to ethyl acetate (In which It is very poorly soluble); and 
this organic phase was then added to the aqueous phase, to which TMZ may have had much 
more affinity. Therefore when the organic phase was evaporated the TMZ was probably not 
entrapped in the PLGA droplets but spread out in the aqueous phase. Hence, the TMZ in the 
aqueous phase may have adsorbed onto the nanoparticle surface only after PLGA NP production 
was complete (upon filtration and stabilization overnight at 4 °C). 
 
Table 7: Stability of TMZ-loaded PLGA NPs  
PLGA- TMZ  size (nm) ZP (mV) PdI 
Day 1 176 ± 6 -4 ± 1 0.05 ± 0,02 
Day 4 813 ± 8 -4 ± 3 0.10 ± 0,04 
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4.4.4 Modification of PLGA NP Production Method 
 
TMZ-PLGA NPs produced with polysorbate 80 
 The TMZ-loaded PLGA nanoparticles produced after modifying the supernatant from 
pluronic f127 to polysorbate 80 in an attempt to produce more stable particles, produced the 
results shown in table 8. 
 
Table 8: TMZ-loaded NPs produced with Polysorbate 80 over time 
 Size(nm) ζ-
potential 
(mV) 
PdI 
day 1 133 ± 6 5± 2 0,09±0,01 
day 2 132± 5 0± 1 0.15±0.02 
day 3 119± 6 0± 1 0.25±0.03 
day 4 117± 4 0± 1 0.21±0.03 
    
 The polydispersity increases from 0.09 to 0.25 in 3 days, indicating that the NPs size in 
the sample are too polydisperse (> 0.1), also explaining the change in average size of the 
nanoparticles. The zeta potential also decreases. As all the parameters vary substantially, one 
can conclude that the particles produced through single emulsion solvent evaporation technique 
using polysorbate 80 instead of pluronic f127, are not stable and the NPs must be produced by 
a different procedure.  
 
TMZ-PLGA NPs produced at half PLGA/TMZ loading percentage 
 TMZ-loaded PLGA particles produced with 0.5 mg instead of 1 mg as used in the previous 
experiments and as described in the initial protocol for producing PLGA NPs through the single 
solvent emulsion evaporation technique. 
 
Table9: TMZ-loaded NPs produced with 5% TMZ (0.5mg) 
 
 
 
 
 
  Size 
(nm) 
ζ-
potential  
(mV) 
PdI 
TMZ/PLGA (5%) 168± 4 -1± 1 0.45±0.03 
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The results in Table 9 show that the aqueous phase used was PBS again and the mass of TMZ 
was 0.5 mg. The polydispersity of the sample was too high (>0,1) and the ζ-potential is very close 
to 0 indicating yet again that TMZ has been adsorbed on the surface and has not been 
encapsulated. If it had been encapsulated, one would expect a zeta potential close to that of the 
unloaded PLGA NPs that have a ZP of around -30 mV when pluronic f127 is used as the stabilizer. 
The results also show a very high polysdispersion (>0.1), an additional factor that makes this 
method unsuitable.  
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5. CONCLUSIONS AND FUTURE PERSPECTIVES  
 This project allowed for a detailed understanding of the behaviour and 
physichochemical properties of TMZ; a drug that is used in wide-scale as an adjuvant 
chemotherapeutic agent. Encapsulating this drug, by developing a nanocarrier, to reduce 
systemic side-effects and increase its bioavailability was the main aim of this project.  
 As confirmed by the experiments carried out, TMZ is amphiphilic. Although successful in 
developing PLGA particles alone, through single solvent emulsion evaporation technique, 
encapsulation of TMZ was not successful in PLGA NPs. As the TMZ molecule is not entirely 
hydrophobic, failure to form PLGA/TMZ droplets -as the organic phase evaporated- may have 
resulted as a consequence of affinity of the compound for the aqueous phase. Further work 
should be carried out using the double-emulsion solvent evaporation technique a method that 
has been developed for encapsulation of hydrophilic molecules. 
 Despite the difficulties in encapsulating TMZ in PLGA, encapsulation in liposomes was 
successful with an encapsulation efficiency of approximately 45-50%, observed upon directly 
bursting the liposomes and measuring the TMZ released. These results are promising, as well as 
novel, as there is no literature reporting TMZ encapsulated in liposomes.  
 Future perspectives are to test the efficacy of these TMZ-loaded liposomes by testing 
their cytotoxicity in glioma cell lines (U87 cell lines) and compare these results to cytotoxicity of 
TMZ alone. Once the efficiency of these liposomes are tested in cells, functionalization with 
ligands specific to allow these NPs to cross the BBB and bind to cells in the brain parenchyma 
would have to be carried out in order to enable the drug to reach its target. To enhance the 
cytotoxicity provided by TMZ, direct inhibitors of DNA-repair enzymes (such as poly (ADP-ribose) 
polymerase, PARP inhibitor, could be encapsulated along with TMZ.  
 Another important barrier to take into consideration in treatment of GBM with TMZ, is 
the high resistance to therapy seen in approximately 60% of patients, due to non-methylation 
of the MGMT gene, the DNA repair enzyme which interferes with the alkylation caused by TMZ. 
A way to circumvent this problem would be to use MGMT-specific siRNA- loaded liposomes, 
functionalized specifically towards the tumour astrocytic cells, in order to block the MGMT gene, 
and thus prevent such high levels of resistance to TMZ chemotherapy.  
 It can be therefore concluded that this dissertation project presents findings that will 
serve as the foundation for future work in the treatment of this specific disease through NP DDS.  
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